Evidence map›Paper›PMID 38779719›Full record

ArticleHaematologica2024

Combination low-intensity chemotherapy plus inotuzumab ozogamicin, blinatumomab and rituximab for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Amber Gibson, Cesar Nunez, Lindsay Robusto, Brianna Kammerer, Miriam Garcia, Michael Roth, Rachna Sheth, Priti Tewari, Aline Hittle, Laurie Toepfer and 6 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Amber GibsonDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX. algibson2@mdanderson.org.
Cesar NunezDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX.
Lindsay RobustoDepartment of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston TX.
Brianna KammererDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX.
Miriam GarciaDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX.
Michael RothDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX.
Rachna ShethDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX.
Priti TewariDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX.
Aline HittleDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX.
Laurie ToepferDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX.
Romeo TorresDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX.
Nicholas J ShortDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Elias JabbourDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Nitin JainDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Branko CuglievanDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX.
David McCallDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, BispecificAntineoplastic Combined Chemotherapy ProtocolsInotuzumab OzogamicinPrecursor B-Cell Lymphoblastic Leukemia-LymphomaRituximabAdolescentChildChild, PreschoolDrug Resistance, NeoplasmFemaleHumansMaleRecurrenceTreatment OutcomeAntibodies, BispecificblinatumomabInotuzumab OzogamicinRituximab

Identifiers

PMID38779719
PMCPMC11367183

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.